Published: 2019-07-25

Prevalence and impact of adiposity and sarcopenia during rheumatoid arthritis: rapid and non-invasive evaluation in Sub-Saharan African women

Maïmouna Touré, Mouhamed T. Diagne, Amadou Badji, Souleymane Thiam, Coumba Diouf, Moustapha Niasse, Mbaye Sene, Abdou Khadre Sow, Aissatou Seck, Salimata D. Houndjo, Mor Diaw, Arame Mbengue, Fatou Bintou Sar, Abdoulaye Bâ, Seydou Diallo, Abdoulaye Samb


Background: Body composition plays a fundamental role in the occurrence of complications in rheumatoid arthritis. Authors conducted this study, which aimed to determine body composition and its effects on physiological status in African sub-Saharan polyarthritis women.

Methods: The anthropometric parameters were measured after an interview and a complete physical examination. The body composition was evaluated using a Tanita® brand bioimpedance meter. Finally, all the patients had a dosage of certain biochemical parameters.

Results: An excess of percent fat mass was noted in more than half of women (59.52%) without loss of muscle mass. At the same time, 30% of women had a significant decrease in the percentage of body water. The BMI did not appear to be an adequate proxy for these changes. Visceral fat level was elevated just in 16% of women, however it would be a determinant of physiological aging of subjects. Dual therapy methotrexate and corticosteroid would have varying effects depending on the duration and the dose of treatment. The basic metabolism in polyarthritic subjects would be dependent on two parameters namely muscle mass and inflammatory state.

Conclusions: Evaluating changes in body composition quickly, non-invasively and inexpensively is possible. It could be useful in the follow-up of rheumatoid arthritis. Managing these changes can reduce cardiovascular morbidity and mortality in rheumatoid arthritis.


Adiposity, Metabolic age, Rheumatoid arthritis, Sarcopenia, Sub-Saharan African women

Full Text:



Nassar K, Janani S, Rachidi W, Mkinsi O. The assessment of muscle function and fall risk in rheumatoid arthritis: assessment tools and treatment effects. Rev Mar Rhum. 2013;25:20-7

Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population based study. Arthritis Rheum. 2005;52(3):722-32.

Doran MF, Pond GR, Crowson CS, O’Fallon WM, Gabriel SE. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum. 2002;46(3):625-31.

Daïen CI, Fesler P. Rheumatoid arthritis: a cardiovascular disease?. Ann Cardio Angio. 2012;61(2):111-7.

Watson DJ, Rhodes T, Guess HA. All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol. 2003;30(6):11962-202.

Soubrier M, Barber Chamoux N, Tatar Z. Cardiovascular risk in rheumatoid arthritis. Joint Bone Spine. 2014;81(4):298-302.

Solomon DH, Curhan GC, Rimm EB, Cannuscio CC, Karlson EW. Cardiovascular risks in women with and without rheumatoid arthritis. Arthritis Rheum. 2004;50(11):3344-9.

Tantayakom P, Koolvisoot A, Arromdee E, Chiowchanwisawakit P, Muangchan C, Katchamart W. Metabolic syndrome is associated with disease activity in patients with rheumatoid arthritis. Joint Bone Spine. 2016;83(5):563-7.

Challal S, Minichiello E, Boissier MC, Semerano L.

Cachexia and adiposity in rheumatoid arthritis. Relevance for disease management and clinical outcomes. Joint Bone Spine. 2016;83(2):127-33.

Elkan AC, Engvall IL, Cederholm T, Hafström I.

Rheumatoid cachexia, central obesity and malnutrition in patients with low-active rheumatoid arthritis: feasibility of anthropometry, Mini Nutritional Assessment and body composition techniques. Eur J Nutr. 2009;48(5):315-22.

Fox KA, Després JP, Richard AJ, Bretté S, Deanfield JE. Does abdominal obesity have a similar impact on cardiovascular disease and diabetes?: a study of 91,246 ambulant patients in 27 European countries. Euro Heart J. 2009;30(24):3055-63.

Janssen I, Baumgartner R, Ross R, Rosenberg IH, Roubenoff R. Skeletal muscle cut points associated with elevated physical disability risk in older men and women. Am J Epidemiol. 2004;159(4):413-21.

Hume R, Weyers E. Relationship between total body water and surface area in normal and obese subjects. J Clin Pathol. 1971;24(3):234-8.

Ottaviani S. Obesity and rheumatoid arthritis. J Rheumat Monographs. 2016;83:29-33.

Gallagher D, Heymsfield SB, Heo M, Jebb SA, Murgatroyd PR, Sakamoto Y. Healthy percentage body fat ranges: an approach for developing guidelines based on body mass index. Am J Clin Nutr. 2000;72(3):694-701.

Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol. 2005;115(5):911-9.

Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008;9(7):629-35.

Chung CP, Oeser A, Solus JF, Avalos I, Gebretsadik T, Shintani A, et al. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atheroscl. 2008;196(2):756-63.

Tournadre A, Pereira B, Dutheil F, Giraud C, Courteix D, Sapin V, et al. Changes in body composition and metabolic profile during IL6 inhibition in rheumatoid arthritis. J Cachexia Sarcopenia Muscle. 2017;8(4):639-46.

Giles JT, Ling SM, Ferrucci L, Bartlett SJ, Andersen RE, Towns M, et al. Abnormal body composition phenotypes in older rheumatoid arthritis patients: association with disease characteristics and pharmacotherapies. Arthritis Care Res. 2008;59(6):807-15.

Roubenoff R, Roubenoff RA, Cannon JG, Kehayias JJ, Zhuang H, Dawson-Hughes B, et al. Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation. J Clin Invest. 1994;93(6):2379-86.

Engvall IL, Elkan AC, Tengstrand B, Tengstrand B, Cederholm T, Brismar K, et al. Cachexia in rheumatoid arthritis is associated with inflammatory activity, physical disability and low bioavailable insulin-like growth factor. Scand J Rheumatol. 2008;37(5):321-8.

Butler RN. Did you say sarcopenia?. Geriatrics. 1993;48(2):11-2.

Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860-7.

Kramer HR, Fontaine KR, Bathon JM, Giles JT. Muscle density in rheumatoid arthritis: associations with disease features and functional outcomes. Arthritis Rheum. 2012;64(8):2438-50.

Cojocarua M, Cojocaru IM, Silosi I, Vrabie CD. Metabolic Syndrome in Rheumatoid Arthritis. J Clin Med. 2012;7(2):148-52.

El Maghraoui A. Denutrition, cachexia and osteoporosis. Rev Rhum Monographique. 2013;80:100-4.

Toms TE, Panoulas VF, John H, Douglas KMJ, Kitas GD. Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60 more than just an anti-inflammatory effect? A cross sectional study. Arthritis Res Ther. 2009;11(4):R110

Zonana-Nacach A, Santana-Sahagun E, Jimenez-Balderas FJ, Camargo-Coronel A. Prevalence and Factors Associated With Metabolic Syndrome in Patients With Rheumatoid Arthritis and Systemic Lupus Erythematosus. J Clin Rheumatol. 2008;14(2):74-7.

Dao HH, Do QT, Sakamoto J. Increased frequency of metabolic syndrome among Vietnamese women with early rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther. 2010;12(6):R218

Crowson CS, Myasoedova E, Davis JM, Matteson EL, Roger VL, Therneau TM, et al. Increased Prevalence of Metabolic Syndrome Associated with Rheumatoid Arthritis in Patients without Clinical Cardiovascular Disease. J Rheumatol. 2011;38(1):29-35.

Raterman HG, Voskuy AE, Dijkmans BA, Nurmohamed MT. Use of methotrexate therapy is not associated with decreased prevalence of metabolic syndrome. Arthritis Res Ther. 2009;11(5):413

Lusa AL, Amigues I, Kramer HR, Dam TT, Giles JT. Indicators of walking speed in rheumatoid arthritis: relative influence of articular, psychosocial, and body composition characteristics. Arthritis Care Res. 2015;67(1):21-31.

Stavropoulos-Kalinoglou A, Metsios GS, Koutedakis Y, Nevill AM, Douglas KM, Jamurtas A, et al. Redefining overweight and obesity in rheumatoid arthritis patients. Ann Rheum Dis. 2007;66(10):1316-21.

Konijn NP, van Tuyl LH, Bultink IE, Lems WF, Earthman CP, van Bokhorst-de van der Schueren MA. Making the invisible visible: bioelectrical impedance analysis demonstrates unfavourable body composition in rheumatoid arthritis patients in clinical practice. Scand J Rheumatol. 2014;43(4):273-8.

Kremers HM, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum. 2004;50(11):3450-7.

Kaufmann J, Kielstein V, Kilian S, Stein G, Hein G. Relation between body mass index and radiological progression in patients with rheumatoid arthritis. J Rheumatol. 2003;30(11):2350-5.

Stefan N, Haring HU. The metabolically benign and malignant fatty liver. Diabetes. 2011;60(8):2011-7.

Baumgartner RN, Chumlea WC, Roche AF. Bioelectric impedance phase angle and body composition. Am J Clin Nutr. 1988;48(1):16-23.

Escalante A, Haas RW, del Rincon I. Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. Arch Intern Med. 2005;165(14):1624-9.